ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2684

Multimodal Analysis Revealed Altered Brain Connectivity Patterns and Neuroinflammatory Processes in the Background of Difficult-To-Treat Rheumatoid Arthritis
Abstract Number: 0705

Multimodal Imaging Evaluation of Patients with Raynaud’s Phenomenon meeting the Criteria for “Early” Systemic Sclerosis according to LeRoy versus Healthy Controls: a Prospective Cross-sectional study
Abstract Number: 1784

Multimodal Preclinical Screening Of Glucocorticoid-Induced Disruption Of Bone Remodeling In Rat
Abstract Number: 1362

Multimodal Spatial and Single-Cell Profiling of Synovial Tissue Reveals Macrophage Programs Associated with Biologic TherapyTreatment Response in Rheumatoid Arthritis
Abstract Number: 0546

Multimorbidity clusters in psoriatic arthritis, psoriasis, and axial spondyloarthritis and their association with healthcare utilization: A population-based study
Abstract Number: 1829

Multiomic Investigation of Juvenile Idiopathic Arthritis Synovium Reveals Immune Cell Heterogeneity
Abstract Number: 2091

Multiplanar MRI Quantification of Effusion-Synovitis: Reliability and Potential Investigative Utility for Inflammation-Mediated Knee Conditions
Abstract Number: 1944

Musculoskeletal Ultrasound Clinic Referral Patterns and Joint Findings in a Tertiary Care Center amongst Patients with Elevated BMI and Inflammatory Arthritis
Abstract Number: 0385

Musculoskeletal Ultrasound Enhances Patient Insight and Clinical Decisions: A Multi-Center Study
Abstract Number: 2579

Mutant COPA Permits Aberrant NETosis and Exacerbates Autoimmune Lung Disease
Abstract Number: PP03

My Journey of Risk, Loss, and Hope: The Role of Multidisciplinary Collaboration in Managing Pregnancy with Takayasu Arteritis
Abstract Number: 0863

Myeloid Dendritic Cell Subsets Characterize Muscle of Inclusion Body Myositis Patients and Correlate with KLRG1+ and TBX21+ CD8+ T cells
Abstract Number: 1246

Myo Vs. Myo-fascial Injection for Myofascial Trigger Points. Is There Really a Difference? A Randomized Controlled Trial
Abstract Number: 0999

Myositis Induced by Histidyl-Transfer tRNA Synthetase is Exacerbated by Membranopathy and Suppressed by Regulatory T Cells
Abstract Number: 1187

Myositis-Specific Antibody Profiles and Factors Associated With Rapidly Progressive Interstitial Lung Disease and Mortality in Antisynthetase Syndrome: A Systematic Review and Meta-Analysis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].